EDP Biotech is touting a biomarker-based blood test that it says can detect the presence of colorectal cancer with 99% sensitivity.
In a statement released today, the Knoxville, TN-based firm said it signed up Tennessee state legislators to "personally experience the ColoMarker test by enrolling in the control study group for EDP's latest research."
The test measures a blood-based biomarker discovered by the company that utilizes inexpensive technology, EDP said. By measuring a biomarker and a testing process based on existing technology, ColoMarker has shown greater than 99% accuracy for detecting colon cancer in stages I, II, and III, and at an affordable cost, the company said.
Based on the encouraging results of preclinical trials, EDP Chief Scientific Officer Dr. Kevin Jones said he believes ColoMarker, used for early cancer detection, will reduce colon cancer deaths in Tennessee and throughout the world.
By AuntMinnie.com staff writers
March 17, 2010
Related Reading
VisEn launches imaging agent, January 19, 2010
Study may show breast cancer without biopsy, December 21, 2009
Siemens touts biomarker study, September 23, 2009
Test may find hidden colorectal cancers: study, February 18, 2009
Copyright © 2010 AuntMinnie.com
